• English
    • German


Technology Secured

Lipocyte BioMed has secured a broad IP-coverage for our technology. The focus on our patents lies on specific mRNAs in relation to individual diseases.

Our patents strategy concentrates on the major markets, i.e., EU, USA, China, and India. So far Lipocyte has developed four patent families. For these families, patents have in part already been granted and in part applications are pending.

Breaking new ground for
diagnostics, therapeutics and prevention


mRNA-analysis of the SAT offers deep and completely new insights into the energy metabolism. Especially with metabolic diseases the current dynamics of the body and influences over life-time play a far greater role than genetic dispositions

Read more


The key to successful treatment of metabolic diseases lies in the intervention with disease-causing on-going biological processes. As the mRNA of the SAT are to a great extent the drivers of pathology of these diseases, they offer a strong lever for therapy.

Read more


A great advantage of mRNA-analysis of the subcutaneous adipose tissue lies in the very early detection of unhealthy developments of the metabolism long before any signs can be seen in blood-analysis or any symptoms become apparent. It is, therefore, a powerful component in preventive personalised medicine.

Read more